Biogen Idec and UCB partner with the ALS Therapy Development Institute to conduct preclinical testing of CDP7657 to treat amyotrophic lateral sclerosis (ALS)

Biogen Idec Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

$26,737.6m on 12/30/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

UCB S.A.

Belgium / Mid-Cap Biopharma ($1-$50 billion)

$7,651.7m on 12/30/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

ALS Therapy Development Institute

U.S. / Non-Profit or Major Disease Foundation

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced